Atlanta, GA August 6, 2019 – Emil Kakkis, MD, PhD, joins the Board of Directors for Odylia Therapeutics.  Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments  for multiple rare and ultra-rare diseases. He brings to Odylia vast knowledge...

06 August, 2019

Lara Aronoff Dorfman joins Odylia Therapeutics as the Director of Business Development.  Her focus for this unique nonprofit biotech company will be raising capital through philanthropy, primarily from foundations and corporate giving.  Increased funds will allow Odylia to have a greater impact on shifting the...

24 June, 2019

Scott Dorfman, Odylia Therapeutics CEO, was recently a featured guest on Partners4Access Weekly Podcast.  A recording of the podcast entitled “Rare Disease, Cell and Gene Therapy Weekly Roundup” can be found here.  Produced by Partners4Access, global experts in access for orphan drug, cell and gene...

13 June, 2019

Odylia CSO Harrison Brown, PhD spoke at the 2019 meeting of the American Society of Gene and Cell Therapy on the issues restricting the development and clinical application of gene therapies for rare genetic diseases. He discussed the specific challenges facing ultra-rare indications, especially those...

02 May, 2019

March 26, 2019 (Boston, MA) Odylia Therapeutics Chief Scientific Officer Harrison Brown led a workshop on the challenges and solutions to the development of AAV gene therapies for rare disorders. Held at the 3rd Annual Gene Therapy For Rare Disorders Conference in Boston, MA, this...

05 April, 2019